MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision diagnostics company, today announced a research collaboration with the Universit...
Novo Nordisk licenses three preclinical drug discovery programmes in cardiovascular diseases discovered and developed by Valo using the Opal Computational ...
The healthcare landscape in Latin America is currently a worldwide priority. Factors such as increasing awareness of precision medicine, the growing preval...
Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic r...
Located in Sapporo, Japan, Hokkaido University Hospital stands as one of the most prominent medical institutions in the country. Affiliated with Hokkaido U...
Syneos Health is evolving its patient recruitment capabilities to further address unmet sponsor, site and patient needs. Through its collaboration with the...
Orion Health is a leading open healthcare platform provider committed to unifying data across complex health systems serving 12 count...
The companies will collaborate to apply ShapeTX’s AAVid™ capsid discovery platform and transgene engineering technology along with Otsuka&...
The principal investigator, Jennifer Ellis, PhD, Associate Professor of Psychiatry and Behavioral Sciences, JHU School of Medicine will be supported by co-...
Peanut allergy currently affects approximately 2% of the general population of Western nations1, and the prevalence of peanut allergy doubled among childre...
Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and l...
“Ono has a strong and proven track record in developing antibody candidates in areas of need, including the development of the anti-PD-1 antibody Opd...
ImmunoGen to Receive $34 Million1 in Upfront and Near-Term Milestone Payments and is Eligible to Receive Potential Regulatory and Commercial Milestone Paym...
The world of drug discovery is about to get a major boost as two cutting-edge technologies join forces. The integration of Serengen's unrivalled DEL techno...
© 2025 Biopharma Boardroom. All Rights Reserved.
